AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
AIM ImmunoTech Inc. reports positive data from Phase 2a study evaluating Ampligen as a part of a regimen for treating colorectal cancer metastatic to the liver proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
New Orleans, Louisiana (PRWEB) April 09, 2022 NEW ORLEANS, La. Two Roswell Park Comprehensive Cancer Center oncologists will discuss promising strategies